

1 **COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme**

2 Clare L. Fasching^{1*}, Venice Servellita^{2,3*}, Bridget McKay¹, Vaishnavi Nagesh¹, James
3 P. Broughton¹, Noah Brazer^{2,3}, Baolin Wang^{2,3}, Alicia Sotomayor-Gonzalez^{2,3}, Kevin
4 Reyes^{2,3}, Jessica Streithorst^{2,3}, Rachel N. Deraney¹, Emma Stanfield¹, Carley G.
5 Hendriks¹, Steve Miller^{2,3}, Jesus Ching¹, Janice S. Chen^{1†}, Charles Y. Chiu^{2,3,4†}

6

7 ¹ Mammoth Biosciences, Inc., Brisbane, CA, USA.

8 ² Department of Laboratory Medicine, University of California San Francisco, San
9 Francisco, CA, USA.

10 ³ UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.

11 ⁴ Department of Medicine, Division of Infectious Diseases, University of California San
12 Francisco, San Francisco, CA, USA.

13 *These authors contributed equally

14 †Co-corresponding authors

15

16 **Abstract**

17 Laboratory tests for the accurate and rapid identification of SARS-CoV-2 variants have
18 the potential to guide the treatment of COVID-19 patients and inform infection control
19 and public health surveillance efforts. Here we present the development and validation
20 of a COVID-19 variant DETECTR[®] assay incorporating loop-mediated isothermal
21 amplification (LAMP) followed by CRISPR-Cas12 based identification of single
22 nucleotide polymorphism (SNP) mutations in the SARS-CoV-2 spike (S) gene. This
23 assay targets the L452R, E484K, and N501Y mutations associated with nearly all

24 circulating viral lineages. In a comparison of three different Cas12 enzymes, only the
25 newly identified enzyme CasDx1 was able to accurately identify all three targeted SNP
26 mutations. We developed a data analysis pipeline for CRISPR-based SNP identification
27 using the assay from 91 clinical samples (Ct < 30), yielding an overall SNP concordance
28 and agreement with SARS-CoV-2 lineage classification of 100% compared to viral
29 whole-genome sequencing. These findings highlight the potential utility of CRISPR-
30 based mutation detection for clinical and public health diagnostics.

31

32 **Introduction**

33 The emergence of new SARS-CoV-2 variants threatens to substantially prolong the
34 COVID-19 pandemic. SARS-CoV-2 variants, especially Variants of Concern (VOCs) (1,
35 2), have caused resurgent COVID-19 outbreaks in the United States (2-5) and
36 worldwide (1, 6, 7), even in populations with a high proportion of vaccinated individuals
37 (8-11). Mutations in the spike protein, which binds to the human ACE2 receptor, can
38 render the virus more infectious and/or more resistant to antibody neutralization,
39 resulting in increased transmissibility (12), and/or escape from immunity, whether
40 vaccine-mediated or naturally acquired immunity (13, 14). Variant identification can also
41 be clinically significant, as some mutations substantially reduce the effectiveness of
42 available monoclonal antibody therapies for the disease (15).

43

44 Tracking the evolution and spread of SARS-CoV-2 variants in the community is critical
45 to inform public policy regarding testing and vaccination, as well as guide contact
46 tracing and containment effects during local outbreaks (16, 17). Virus whole-genome

47 sequencing (WGS) and single nucleotide polymorphism (SNP) genotyping are
48 commonly used to identify variants Harper, 2021 #100;Oude Munnink, 2021 #99}, but
49 can be limited by long turnaround times and/or the requirement for bulky and expensive
50 laboratory instrumentation. Diagnostic assays based on clustered interspaced short
51 palindromic repeats (CRISPR) (18) have been developed for rapid detection of SARS-
52 CoV-2 in clinical samples (13, 19-22),, and a few have obtained Emergency Use
53 Authorization (EUA) by the US Food and Drug Administration (FDA) (23, 24). Some
54 advantages of these assays for use in laboratory and point of care settings include low
55 cost, minimal instrumentation, and a sample-to-answer turnaround time of under 2
56 hours (19, 22, 25, 26).

57
58 Here we present the development of a CRISPR-based COVID-19 variant DETECTR[®]
59 assay (henceforth abbreviated as DETECTR[®] assay) for the detection of SARS-CoV-2
60 mutations and evaluate its performance on 91 clinical samples using WGS as a
61 comparator method (**Fig. 1A**). The assay combines RT-LAMP pre-amplification followed
62 by fluorescent detection using a CRISPR-Cas12 enzyme. We perform a comparative
63 evaluation of multiple candidate Cas12 enzymes and demonstrate that robust assay
64 performance depends on the specificity of the newly identified CRISPR-Cas12 enzyme
65 called CasDx1 in identifying three key SNP mutations of functional relevance in the
66 spike protein, N501Y, L452R, and E484K (27).

67

68 **Results**

69 **Identifying the optimal CRISPR-Cas12 enzyme for SNP detection**

70 To determine the optimal Cas12 enzyme for SNP detection, we evaluated three
71 different CRISPR-Cas effectors with trans-cutting activity: LbCas12a, AsCas12a, and a
72 novel Cas12 enzyme called CasDx1. We initially screened guide RNAs (gRNAs) with
73 CasDx1 and LbCas12a for activity on synthetic gene fragments encoding regions of the
74 SARS-CoV-2 S-gene with either wild-type (WT) or mutant (MUT) sequences at amino
75 acid positions 452, 484, and 501 (**Fig. 1B-C**). From this initial activity screen, we
76 identified the top-performing gRNAs for each S-gene variant encoding either L452R,
77 E484K or N501Y (**Fig. 1D**). Further evaluation of these guides using CasDx1,
78 LbCas12a and AsCas12a with their cognate gRNAs on synthetic gene fragments
79 revealed differences in SNP differentiation capabilities, with CasDx1 showing the
80 clearest SNP differentiation between wild-type (WT) and mutant (MUT) sequences for
81 all three S-gene variants (**Fig. 1D and Fig. S1A**). In comparison, LbCas12a was
82 capable of differentiating SNPs at positions 452 and 484, but not 501, whereas
83 AsCas12a was only able to differentiate the SNP at position 452 (**Fig. 1D and Fig.**
84 **S1A**).

85

86 We next tested SNP differentiation capabilities on heat-inactivated viral cultures using
87 the full DETECTR[®] assay, consisting of RNA extraction, multiplexed RT-LAMP
88 amplification (**Fig. 1C**), and CRISPR-Cas12 detection with guide RNAs targeting part of
89 the spike receptor-binding domain (RBD) (**Fig. 1B**). The LAMP primer design
90 incorporated two sets of six primers each, with both sets generating overlapping spike
91 RBD amplicons that spanned the L452R, E484K, and N501Y mutations. We chose to
92 adopt a redundant LAMP design for two reasons: first, this approach was shown to

93 improve detection sensitivity in initial experiments; second, we sought to increase assay
94 robustness given the continual emergence of escape mutations in the spike RBD
95 throughout the course of the pandemic (13). The tested viral cultures included an
96 ancestral SARS-CoV-2 lineage (WA-1) containing the wild-type spike protein (D614)
97 targeted by the approved mRNA (Pfizer and Moderna) (28, 29) and DNA adenovirus
98 vector (Johnson and Johnson) (30) vaccines, variants being monitored (VBM) that
99 were previously classified as VOCs or variants of interest (VOIs), including Alpha
100 (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.427 and B.1.429), Kappa
101 (B.1.617.1), and Zeta (P.2) lineages, and the current VOC Delta (B.1.617.2) lineage
102 (31). Heat-inactivated viral culture samples representing the seven SARS-CoV-2
103 lineages were quantified by digital droplet PCR across a 4-log dynamic range and used
104 to evaluate the analytical sensitivity of the pre-amplification step. RT-LAMP amplification
105 was evaluated using six replicates from each viral culture. We observed consistent
106 amplification for all seven SARS-CoV-2 lineages with 10,000 copies of target input per
107 reaction (200,000 copies/mL) (**Fig. 1E**), which is comparable to the target input of
108 >200,000 copies/mL viruses (<30 Ct value) required for sequencing workflows used in
109 SARS-CoV-2 variant surveillance (32, 33).

110

111 To evaluate the specificity of the different Cas12 enzymes, amplified material from each
112 viral culture was pooled and the SNPs resulting in the L452R, E484K and N501Y
113 mutations were detected using CasDx1, LbCa12a and AsCas12a. Similar to the results
114 found using gene fragments, CasDx1 correctly identified the wild-type (WT) and
115 mutational (MUT) targets at positions 452, 484 and 501 in each LAMP-amplified, heat-

116 inactivated viral culture (**Fig. 1F and Fig. S1B**). In comparison, LbCas12a was capable
117 of differentiating WT from MUT at position 501 on LAMP-amplified viral cultures but
118 showed much higher background for the WT target at position 452 and higher
119 background for both WT and MUT targets at position 484 for (**Fig. 1F and Fig. S1B**).
120 Additionally, AsCas12a was able to differentiate WT from MUT targets at position 452
121 albeit with substantial background but was unable to differentiate WT from MUT targets
122 at positions 484 and 501 (**Fig. 1F and Fig. S1B**). From these data, we concluded that
123 CasDx1 would provide more consistent and accurate calls for the L452R, E484K and
124 N501Y mutations. We thus proceeded to further develop the assay using only the high-
125 fidelity CasDx1 enzyme.
126

128 **Fig. 1. Design and Workflow for the DETECTR[®] assay.** (A) Workflow comparison
129 between the DETECTR[®] assay and SARS-CoV-2 whole-genome sequencing (WGS).
130 (B) Schematic of CRISPR-Cas gRNA design for SARS-CoV-2 S gene mutations. (C)
131 Schematic of multiplexed RT-LAMP primer design showing the SARS-CoV-2 S gene
132 mutations and gRNA positions. (D) Heat map comparison of three different Cas12
133 enzymes tested using 10 nM PCR-amplified synthetic gene fragments. (E) Dot plot
134 showing the number (n=6) of positive replicates across a 4-log dynamic range of the
135 RT-LAMP products (F) Heat map comparison of end-point fluorescence of three
136 different Cas12 enzymes tested against heat-inactivated viral cultures. Replicates (n=6)
137 generated using RT-LAMP were pooled and CRISPR-Cas12 reactions were then run in
138 triplicate (n=3).

139

140 **Development of a data analysis pipeline for calling COVID-19 variant SNPs with** 141 **the DETECTR[®] assay**


142 To develop a data analysis pipeline for calling SARS-CoV-2 SNP mutations and assign
143 lineage classifications with the DETECTR[®] assay (**Fig. 2A-B**), we first used data
144 collected from SNP synthetic gene fragment controls (n=279) that included all
145 mutational combinations of 452, 484 and 501 (see Methods). Based on the control
146 sample data, we generated allele discrimination plots (34, 35) to define boundaries that
147 separate the WT and MUT signals (**Fig. S4A**). Clear differentiation between WT and
148 MUT signals was observed when plotting the ratio against the average of the WT and
149 MUT transformed values on a mean average (MA) plot (34, 35) (**Fig. S4B**), with 100%
150 concordance for SNP identity at positions 452, 484, and 501 for the control samples.

151

152 **Performance evaluation of the DETECTR[®] assay using clinical samples**

153 Next, we assembled a blinded dataset consisting of 93 COVID-19 positive clinical
154 samples (previously analyzed by viral WGS) and the SNP controls run in parallel. These
155 samples were extracted, amplified in triplicate RT-LAMP reactions (**Fig. S2**), and
156 processed further as triplicate CasDx1 reactions for each LAMP replicate (**Fig. S3**). A
157 total of nine replicates were thus generated for each sample to detect WT or MUT SNPs
158 at positions 452, 484, and 501. The DETECTR[®] data analysis pipeline was then applied
159 to each sample to provide a final lineage categorization (**Fig. 2A-C**). For a biological
160 RT-LAMP replicate to be designated as either WT or MUT, the same call needed to be
161 made from all three technical CasDx1 replicates (**Fig. S5A**). A final SNP mutation call
162 was made based on ≥ 1 of the same calls from the three biological replicates, with
163 replicates that were designated as a No Call ignored (**Fig. S5A-C**). After excluding two
164 samples that were considered invalid because the fluorescence intensity from RT-LAMP
165 amplification did not reach a pre-established threshold determined using receiver-
166 operator characteristic (ROC) curve analysis (**Fig. S2 and Fig. S6**), we evaluated a total
167 of 807 CasDx1 signals from the 91 remaining clinical samples, generating up to 9
168 replicates for each clinical sample (**Fig. S5B**). Differentiation of WT and MUT signals
169 according to the allele discrimination plots was more pronounced at positions 484 and
170 501 than position 452 (**Fig. S4**), whereas the MA plots showed clear separation of WT
171 and MUT calls for all three positions (**Fig. 3A and Fig. S4**). The variant calls made on
172 each sample were consistent with the difference in median values of the log-
173 transformed signals as determined using the data analysis pipeline (**Fig. S7**).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



175 **Fig. 2. DETECTR[®] data analysis pipeline for SARS-CoV-2 SNP mutation calling.**

176 (A) Interpretation table summarizing the SARS-CoV-2 mutations in this study
177 associated with the corresponding lineage classification. (B) Schematic of data analysis
178 pipeline describing the RT-LAMP QC and subsequent CasDx1 signal scaling. The
179 scaled signals were compared across SNPs and the calls were made for each RT-
180 LAMP replicate. The combined replicate calls defined the mutation call, which informed
181 the final lineage classification. (C) Three representative clinical samples of different
182 SARS-CoV-2 lineages depict the workflow of the DETECTR[®] assay. Raw fluorescence
183 curves of each sample run in RT-LAMP amplification and subsequent triplicate
184 DETECTR[®] reactions targeting both WT and MUT SNPs for L452(R), E484(K), and
185 N501(Y). Box plot visualization of the end point fluorescence in DETECTR[®] across each
186 SNP for the three representative clinical samples. Calls were made for each SNP by
187 evaluating the median values of the DETECTR[®] calls and overall calls through the
188 LAMP replicates, and given a designation of WT, MUT, or NoCall. Final calls are made
189 on the lineage determined by each SNP. Blue represents WT and green represents
190 MUT, with RT-LAMP replicates (n = 3), CasDx1 replicates (n = 3 per LAMP replicate)
191 and shading around kinetic curves indicates $\pm 1.0SD$.

192


193 We then unblinded the viral WGS results to evaluate the accuracy of the DETECTR[®]
194 assay for SNP calls and lineage classification. There were 14 discordant SNP calls out
195 of 272 (94.9% SNP concordance) distributed among 11 clinical samples out of 91 (Fig.
196 **S8A-C**). Among the 11 discordant samples, one sample (COVID-31) was designated a
197 'no call' at position 452 by viral WGS and thus lacked a comparator, two samples were

198 designated a 'no call' due to flat WT and MUT curves (COVID-41 and COVID-73), four
199 samples had similar WT and MUT curve amplitudes, suggesting a mixed population
200 (COVID-03, COVID-56, COVID-61 and COVID-81) (**Fig. S8A**), and four samples had
201 SNP assignments discordant with those from viral WGS (COVID-12, COVID-13,
202 COVID-20 and COVID-63) (**Fig. S8A**).

203
204 Given that the comparison data had been collected over an extended time period, we
205 surmised that sample stability issues arising from aliquoting and multiple freeze-thaw
206 cycles may have accounted for the observed discrepancies. To further investigate this
207 possibility, the 11 discordant clinical samples were re-extracted from original respiratory
208 swab matrix and re-analyzed by running both viral WGS and the DETECTR[®] assay in
209 parallel. Re-testing of the samples resulted in nearly complete agreement between the
210 two methods, with the exception of two SNPs that were identified as E484Q in two
211 samples by WGS but were incorrectly called E484 (WT) by the DETECTR[®] assay (**Fig.**
212 **3B-C and Fig. S8D**). Thus, based on discrepancy testing, the positive predictive
213 agreement (PPA) between the DETECTR[®] assay and viral WGS at all three WT and
214 MUT SNP positions was 100% (272 of 272, $p < 2.2e-16$ by Fisher's Exact Test) (**Fig.**
215 **3D**). The corresponding negative predictive agreement (NPA) was 91.4% as the E484Q
216 mutation for two SNPs was incorrectly classified as WT. Nevertheless, the final viral
217 lineage classification for the 91 samples after discrepancy testing showed 100%
218 agreement with viral WGS (**Fig. 3D and Table S1**).

219

220



221

222 **Fig. 3. Evaluation of the DETECTR® assay compared to SARS-CoV-2 Whole-**

223 **Genome Sequencing. (A) MA-plots showing CasDx1 SNP detection replicates (n =**

224 807) for each SARS-CoV-2 mutation across 91 clinical samples. WT is denoted by blue
225 dots, MUT is denoted by green dots, NoCall is denoted by orange dots and NTC is
226 denoted by grey dots. **(B)** Alignment of final mutation calls comparing the DETECTR[®]
227 and SARS-CoV-2 WGS assay results across 91 clinical samples after discordant
228 samples (indicated by red asterisk) were resolved. **(C)** Final lineage classification on
229 each clinical sample by the DETECTR[®] assay compared to the SARS-CoV-2 lineage
230 determined by viral WGS. **(D)** Final Positive Predictive Agreement (PPA), Negative
231 Predictive Agreement (NPA) and concordance values for each WT and MUT SNP from
232 the evaluation of the DETECTR[®] assay against the SARS-CoV-2 WGS comparator
233 assay after discordant samples were resolved.

234

235 **Discussion**

236 In this study, we developed a CRISPR-based DETECTR[®] assay for the detection of
237 SARS-CoV-2 variants. We evaluated three CRISPR-Cas12 enzymes, two commercially
238 available (LbCas12a from NEB and AsCas12a from IDT) and one proprietary (CasDx1
239 from Mammoth Biosciences). Based on a head-to-head comparison of these enzymes,
240 we observed clear differences in performance, with CasDx1 demonstrating the highest
241 fidelity as the only enzyme able to reliably detect all three of the targeted SNPs. A data
242 analysis pipeline was developed to differentiate between WT and MUT signals with the
243 DETECTR[®] assay, yielding an overall SNP concordance of 100% (272/272 total SNP
244 calls) and 100% agreement with lineage classification compared to viral WGS. Taken
245 together, these findings show robust agreement between the DETECTR[®] assay and
246 viral WGS for identification of SNP mutations and variant categorization. Thus, the

247 DETECTR[®] assay provides a faster and simpler alternative to sequencing-based
248 methods for COVID-19 variant surveillance.

249

250 Our results show that the choice of Cas enzyme is important to maximize the accuracy
251 of CRISPR-based diagnostic assays and may need to be tailored to the site that is
252 being targeted. As currently configured with only three SNP targets, the DETECTR[®]
253 assay cannot resolve individual major variants, except for Alpha. However, given the
254 rapid emergence and dynamic shifts in the distribution of variants over time (13), it is
255 likely that tracking of key mutations, several of which are suspected to arise by
256 convergent evolution (36), rather than tracking of variants, will be critical for surveillance
257 as the pandemic continues. Furthermore, we also develop a data analysis pipeline for
258 CRISPR-based SNP calling that can readily incorporate additional targets and offers a
259 blueprint for automated interpretation of fluorescent signals that will become more
260 complex as the degree of multiplexing increases.

261

262 Although CRISPR-based diagnostic assays have been previously demonstrated for the
263 detection of SARS-CoV-2 variants, these studies have limitations in coverage of
264 circulating lineages and in the extent of clinical sample evaluation. For example, the
265 miSHERLOCK variant assay uses LbCas12a (NEB) to detect N501Y, E484K and
266 Y144Del covering eight lineages (WA-1, Alpha, Beta, Gamma, Eta, Iota, Mu and Zeta)
267 and was tested only on contrived samples (RNA spiked into human saliva) (20).

268 Additionally, the SHINEv2 assay uses LwaCas13a to detect 69/70Del, K417N/T, L452R
269 and 156/157Del + R158G covering eight lineages (WA-1, Alpha, Beta, Gamma, Delta,

270 Epsilon, Kappa and Mu) and was tested with only the 69/70Del gRNAs on 20 Alpha-
271 positive NP clinical samples (37). In comparison, the DETECTR[®] assay presented here
272 uses CasDx1 to detect N501Y, E484K and L452R covering 11 lineages (WA-1, Alpha,
273 Beta, Gamma, Delta, Epsilon, Eta, Iota, Kappa, Mu and Zeta) and 91 clinical samples
274 representing seven out of the 11 lineages were tested with successful detection of all 7.
275

276 Some limitations of our study are as follows. First, as previously mentioned, the
277 DETECTR[®] assay currently detects only three SNPs, which may not provide enough
278 resolution to identify a specific lineage. Second, we observed variable performance of
279 the assay in SNP discrimination, with more potential overlap in the calls between WT
280 and MUT for the 452 position than for the other two sites, increasing the risk of
281 misidentification. Third, our 484 gRNA was unable to differentiate E484Q from E484
282 (WT) in clinical samples, which could impact the accuracy of lineage classification (we
283 note, however, that the E484Q mutation corresponds to a different nucleotide position in
284 the affected 484 codon than the E484K mutation). These first 3 limitations could
285 potentially be addressed by the incorporation of additional gRNAs to the assay to
286 provide specific and redundant coverage and to improve identification of specific
287 lineages. Fourth, due to the multiplexed S-gene LAMP primer design, the limit of
288 detection of the DETECTR[®] assay is higher than our previously published SARS-CoV-2
289 DETECTR[®] assay (19), and thus only clinical samples with a Ct < 30 were tested in our
290 study. Incorporation of the N-gene target as a separate reaction in the assay may be
291 necessary for covering the dynamic range of COVID-19 positive samples if
292 simultaneous detection and SNP/variant identification is desired. Finally, the current

293 study focuses on the development and validation of a variant DETECTR[®] assay using
294 conventional laboratory equipment. Future work will involve implementation onto
295 automated, portable systems for use in point of care settings.

296

297 In the near term, we suggest the use of the DETECTR[®] assay as an initial screen for
298 the presence of a rare or novel variant (e.g., carrying both L452R and E484K or carrying
299 all three SNPs) that could be reflexed to viral WGS. As the sequencing capacity for
300 most clinical and public health laboratories is limited, the DETECTR[®] assay would thus
301 enable rapid identification of variants circulating in the community to support outbreak
302 investigation and public health containment efforts. Furthermore, identification of
303 specific mutations associated with neutralizing antibody evasion, such as E484K (14),
304 could inform patient care with regards to the use of monoclonal antibodies that remain
305 effective in treating the infection (15). As the virus continues to mutate and evolve, the
306 DETECTR[®] assay can be readily reconfigured by validating new gRNAs and pre-
307 amplification LAMP primers and gRNAs that target emerging mutations with clinical and
308 epidemiological significance. For example, we postulate that the newly emerging
309 Omicron variant, containing at least 30 mutations in the spike protein and 11 mutations
310 in the spike RGD region targeted by the assay, could be detected by increasing
311 degeneracy in the LAMP primers and adding at least one gRNA to be able to distinguish
312 this variant from the others. Over the longer term, a validated CRISPR assay that
313 combines SARS-CoV-2 detection with variant identification would be useful as a tool for
314 simultaneous COVID-19 diagnosis in individual patients and surveillance for infection
315 control and public health purposes.

316 **Materials and Methods**

317

318 **Human Sample Collection and Ethics Statement**

319 Remnant nasopharyngeal and/or oropharyngeal (NP/OP) samples and plasma
320 samples from laboratory confirmed SARS-CoV-2 positive patients were retrieved from
321 the UCSF Clinical Laboratories and stored in a biorepository until processed. Remnant
322 sample biobanking was performed with a waiver of consent and according to no-subject
323 contact study protocols approved by the UCSF Institutional Review Board (protocol
324 numbers 10-01116 and 11-05519).

325

326 **Synthetic Gene Fragments**

327 Wild-type (WT) and mutant (MUT) synthetic gene fragments (Twist) were PCR amplified
328 using NEB 2x Phusion Master Mix following the manufacturer's protocol. The amplified
329 product was cleaned using AMPure XP beads following manufacturers protocol at a
330 0.7x concentration. The product was eluted in nuclease-free water and normalized to 10
331 nM. All nucleic acids used in this study are summarized in **Table S2**.

332

333 **Clinical sample acquisition and extraction**

334 De-identified residual SARS-CoV-2 RT-PCR positive nasopharyngeal and/or
335 oropharyngeal (NP/OP) swab samples in universal transport media (UTM) or viral
336 transport media (VTM) were obtained from the UCSF Clinical Microbiology Laboratory.
337 All samples were stored in a biorepository according to protocols approved by the

338 UCSF Institutional Review Board (protocol number 10-01116, 11-05519) until
339 processed.

340

341 All NP/OP swab samples obtained from the UCSF Clinical Microbiology Laboratory
342 were pretreated with DNA/RNA Shield (Zymo Research, # R1100-250) at a 1:1 ratio.

343 The Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek, # M6246-03) on the KingFisher

344 Flex (Thermo Fisher Scientific, # 5400630) was used for viral RNA extraction using an

345 input volume of 200 μ l of diluted NP/OP swab sample and an elution volume of 100 μ l.

346 The Taqpath™ COVID-19 RT-PCR kit (Thermo Fisher Scientific) was used to determine
347 the N gene cycle threshold values.

348

349 **Heat-inactivated culture acquisition and extraction**

350 Heat-inactivated cultures of SARS-CoV-2 Variants Being Monitored (VBM), Variants of

351 Concern (VOC) or Variants of Interest (VOI) were provided by the California Department

352 of Public Health (CDPH).

353

354 RNA from heat-inactivated SARS-CoV-2 VBM/VOC/VOI isolates were extracted using

355 the EZ1 Virus Mini Kit v2.0 (Qiagen, # 955134) on the EZ1 Advanced XL (Qiagen, #

356 9001875) according to the manufacturer's instructions. For each culture, six replicate

357 LAMP reactions were pooled into a single sample. DETECTR® was performed on a

358 1:10 dilution of the 10,000 cp/rxn LAMP amplification products.

359

360 **COVID-19 variant DETECTR® assay**

361 Two LAMP primer sets, each containing 6 primers, were designed to target the L452R,
362 E484K and N501Y mutations in the SARS-CoV-2 Spike (S) protein (Supplemental
363 Table). Sets of LAMP primers were designed from a 350 bp target sequence spanning
364 the 3 mutations using Primer Explorer V5 (<https://primerexplorer.jp/e/>). Candidate
365 primers were manually evaluated for inclusion using the OligoCalc online
366 oligonucleotide properties calculator (38) while ensuring that there was no overlap with
367 either primers from the other set or guide RNA target regions that included the L452R,
368 E484K, and N501Y mutations.

369

370 Multiplexed RT-LAMP was performed using a final reaction volume of 50 μ l, which
371 consisted of 8 μ l RNA template, 5 μ l of L452R primer set (Eurofins Genomics), 5 μ l of
372 E484K/N501Y primer set, 17 μ l of nuclease-free water, 1 μ l of SYTO-9 dye
373 (ThermoFisher Scientific), and 14 μ l of LAMP mastermix. Each of the primer sets
374 consisted of 1.6 μ M each of inner primers FIP and BIP, 0.2 μ M each of outer primers F3
375 and B3, and 0.8 μ M each of loop primers LF and LB). The LAMP mastermix contained 6
376 mM of $MgSO_4$, isothermal amplification buffer at 1X final concentration, 1.5 mM of dNTP
377 mix (NEB), 8 units of Bst 2.0 WarmStart DNA Polymerase (NEB), and 0.5 μ l of
378 WarmStart RTx Reverse Transcriptase (NEB). Plates were incubated at 65°C for 40
379 minutes in a real-time Quantstudio™ 5 PCR instrument. Fluorescent signals were
380 collected every 60 seconds

381

382 40nM CasDx1 (Mammoth Biosciences), LbCas12a (EnGen® Lba Cas12a, NEB) or
383 AsCas12a (Alt-R® A.s. Cas12a, IDT) protein targeting the WT or MUT SNP at L452(R),

384 E484(K) or N501(Y) was incubated with 40nM gRNA in 1X buffer (MBuffer3 for CasDx1,
385 NEBuffer r2.1 for LbCas12a and AsCas12a) for 30 min at 37°C. Dx1 gRNAs were used
386 with both CasDx1 and LbCas12a, whereas AsCas12a gRNAs were used with
387 AsCas12a (**Table S2**). 100nM ssDNA reporter (/5Alex594N/TTATTATT/3IAbRQSp/
388 IDT) was added to the RNA-protein complex. 18µL of this DETECTR® master mix was
389 combined with 2 µL target amplicon. The DETECTR® assays were monitored for 30 min
390 at 37°C in a plate reader (Tecan).

391

392 **Digital PCR**

393 Samples were evaluated at 3 dilutions (1:100; 1:1,000; and 1:10,000) using the ApexBio
394 Covid-19 Multiplex Digital PCR Detection Kit (Stilla Technologies) according to the
395 manufacturer's protocol. The controls (positive and negative provided by UCSF, the Kit
396 Controls, and an internal control) were run with the samples in duplicate. The dilutions
397 were used to determine the most accurate concentration which was determined from
398 the N gene concentration.

399

400 **Sequencing methods**

401 Complementary DNA (cDNA) synthesis from RNA via reverse transcription and tiling
402 multiplexed amplicon PCR were performed using SARS-CoV-2 primers version 3
403 according to a published protocol (39). Libraries were constructed by ligating adapters
404 to the amplicon products using NEBNext Ultra II DNA Library Prep Kit for Illumina (New
405 England Biolabs, # E7645L), barcoding using NEBNext Multiplex Oligos for Illumina
406 (New England Biolabs, # E6440L), and purification with AMPure XP (Beckman-Coulter,

407 # 63880). Final pooled libraries were sequenced on either Illumina NextSeq 550 or
408 Novaseq 6000 as 1x300 single-end reads (300 cycles).
409
410 SARS-CoV-2 viral genome assembly and variant analyses were performed using an in-
411 house bioinformatics pipeline. Briefly, sequencing reads generated by Illumina
412 sequencers (NextSeq 550 or NovaSeq 6000) were demultiplexed and converted to
413 FASTQ files using bcl2fastq (v2.20.0.422). Raw FASTQ files were first screened for
414 SARS-CoV-2 sequences using BLASTn (BLAST+ package 2.9.0) alignment against the
415 Wuhan-Hu-1 SARS-CoV-2 viral reference genome (NC_045512). Reads containing
416 adapters, the ARTIC primer sequences, and low-quality reads were filtered using
417 BBDuk (version 38.87) and then mapped to the NC_045512 reference genome using
418 BMap (version 38.87). Variants were called with CallVariants and a depth cutoff of 5
419 was used to generate the final assembly. Pangolin software (version 3.0.6) (40, 41) was
420 used to identify the lineage. Using a custom in-house script, consensus FASTA files
421 generated by the genome assembly pipeline were scanned to confirm L452R, E484K,
422 and N501Y mutations.

423

424 **Discordant sample retesting**

425 Eleven samples were re-extracted as described above for the NP/OP swab samples
426 and evaluated by viral WGS as described above. The samples were then thawed (XXX
427 freeze/thaws) and amplified using the LAMP protocol described above and evaluated
428 using the DETECTR[®] assay as described above.

429

430 **DETECTR[®] data analysis pipeline**

431 Quality Control Metric for the LAMP Reaction

432 Prior to processing DETECTR[®] data from the clinical samples, we collected data
433 indicating the success or failure of the samples to amplify in the LAMP reaction. The
434 absolute truth was based on visual inspection of LAMP curves This absolute truth was
435 used to develop thresholds for the LAMP reactions. The positive and negative controls
436 from the LAMP reactions were used to derive the thresholds to qualify the samples. Two
437 sets of thresholds were used: time threshold and fluorescence rate threshold. The
438 positive LAMP controls were assumed to represent an ideal sample and displayed a
439 classic sigmoidal rise of fluorescence over time and the NTC represented the
440 background fluorescence. It was hypothesized that a sample will ideally have positive
441 control like fluorescence kinetics. However due to the presence of high background in
442 some samples, a mean value between controls for each plate was chosen as threshold.
443 After this, the fluorescence values at a time threshold of 18 minutes were collected. The
444 time point is of importance here to rule out those samples that would amplify closer to
445 the endpoint, signifying the LAMP intermediates to be the majority contributors of the
446 rise in the signal and not the actual sample itself. A score was assigned for each sample
447 which was calculated as a ratio of rate of fluorescence rate threshold to the rate of
448 fluorescence value at 18 minutes for each sample. The hypothesis is that if this ratio of
449 rate of fluorescence between controls and samples is less than 1, then samples have
450 failed to reach the minimum fluorescence required to be called out as amplified and if
451 the ratio is greater than or equal to 1, then samples have amplified sufficiently. To

452 identify the exact score value for a qualitative QC metric, an ROC analysis was done on
453 scores and the absolute truth (**Fig. S6**).

454

455 Data Analysis for CRISPR-based SNP calling

456 Each well has a guide specific to the mutant or the wild-type SNP. The comparison is
457 important to assign a genotypic call to the sample. The DETECTR[®] reactions across the
458 plate are not comparable to each other. For this purpose, the endpoint fluorescence
459 intensities are normalized in each well to its own minimum intensity. This term is called
460 fluorescence yield. The fluorescence yield can be compared across wells in a plate
461 under the assumption that each well will have a similar minimum fluorescence starting
462 point. Irrespective of the highest levels of the fluorescence intensities observed across
463 samples, the yield for a given target must ideally remain the same assuming that similar
464 concentrations of samples/target are being compared. This aids in normalizing the
465 signal and comparing replicates across the wells in the same plate.

$$466 \quad F_y = \max(F)/\min(F)$$

467 The wildtype and mutant target guides on NTC must ideally not show any change in
468 intensity over time. The fluorescence yield for NTC must remain constant across
469 replicates, plates and close to 1.

$$470 \quad F_y(\text{NTC}) = 1$$

471 On the contrary, if a sample has a fluorescence yield of 1, then it qualifies for a No Call.

472

473 *General rules for variant calling*

474 1. NTC was assigned NTC

- 475 2. If the Contrast of the sample for a SNP was between minimum and maximum
476 contrast for the plate, then the sample is assigned a NoCall.
477 3. If the Size of the sample is lower than the Size of the NTC on the plate, then the
478 sample is assigned a NoCall.

479
$$C_{min}(NTC-snp) \leq C(sample-snp) \leq C_{max}(NTC-snp) \rightarrow \text{NoCall}$$

480
$$S_{min}(NTC-snp) \leq S(sample-snp) \leq S_{max}(NTC-snp) \rightarrow \text{NoCall}$$

481
$$\log_2(Fy(WT)) > \log_2(Fy(M)) \rightarrow \text{Wild Type}$$

482
$$\log_2(Fy(WT)) < \log_2(Fy(M)) \rightarrow \text{Mutant}$$

483

484 SNP Calls

485 We used the following procedure to evaluate the concordance between sequencing and
486 DETECTR[®] technologies for genotypic classification of the clinical cohort dataset.
487 First, we considered all samples and SNPs for which both sequencing and DETECTR[®]
488 data was present in the distributed files by matching the SNP IDs and sample names.
489 This included cleaning and curing the dataset which had failed LAMP reactions and
490 identifying WT and MUT based on the spacer fluorescent. This yielded a preliminary
491 data set containing 279 calls across three SNPs against 93 samples. After eliminating
492 samples that had failed to amplify in the LAMP reaction but were assigned a genotype,
493 the resulting final analysis data consisted of 272 calls (WT, MUT and NoCall) spread
494 across three SNPs and 91 samples. For each of the three SNPs in the analysis data
495 set, we identified and recorded both sequencing and DETECTR[®] genotypes (including
496 NoCalls and LAMP Fails) for each of the 93 patients. The 91 patients include the
497 individuals for whom actual sequencing data was available.

498

499 **Statistical analysis**

500 SNP Calls

501 For each SNP in the analysis, we computed a variety of statistics evaluating the
502 concordance between genotype calls on the two different technologies. The concordant
503 and discordant genotypes were visualized through contingency tables. For each SNP,
504 there are three possible genotypes (WT, MUT and No Call). The concordance rates
505 were calculated without the samples that failed the LAMP reaction (**Fig. 3B and Table**
506 **S1**). The 2x2 cross tables classify all three SNPs across all the samples between
507 sequencing and DETECTR[®] technologies (**Fig. 3B and Table S1**). The data
508 transformation and statistical analysis was done in R (42).

509

510 **Acknowledgments**

511 We thank the UCSF Center for Advanced Technology core facility (Delsy
512 Martinez and Tyler Miyasaki) for their efforts in high-throughput sequencing of viral
513 cDNA libraries using the Illumina NovaSeq 6000 instrument, and Mary Kate Morris from
514 the California Department of Public Health for providing the heat-inactivated viral
515 cultures. We also thank Lucas Harrington and Teresa Peterson for their critical review of
516 this manuscript.

517 This work has been funded by the Innovative Genomics Institute (IGI) at UC
518 Berkeley and UC San Francisco (C.Y.C.), the Sandler Program for Breakthrough
519 Biomedical Research (C.Y.C.), US Centers for Disease Control and Prevention contract
520 75D30121C10991 (C.Y.C.), and Mammoth Biosciences.

521

522 **Author contributions**

523 C.L.F., J.S.C., and C.Y.C. conceived and designed the study. C.Y.C. and V.S.
524 coordinated the SARS-CoV-2 whole-genome sequencing efforts and RT-LAMP primer
525 design and testing. C.L.F., J.P.B., J.C., and J.S.C. designed guide RNAs for CRISPR-
526 Cas12 testing. B.M., J.P.B., R.N.D., E.S., and C.G.H. tested guide RNAs and ran
527 DETECTR[®] experiments. V.S., N.B., B.W., A.S.-G., K.R., J.S., S.M., and C.Y.C.
528 collected samples. C.L.F., V.S., B.M., V.N., J.P.B., J.C., J.S.C., and C.Y.C. analyzed
529 data. C.L.F., V.S., V.N., B.M., J.P.B., J.C., J.S.C., and C.Y.C. wrote the manuscript. All
530 authors read the manuscript and agree to its contents.

531

532 **Competing interests**

533 C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and
534 receives research support from Abbott Laboratories, Inc. C.L.F., B.M., V.N., J.P.B.,
535 R.N.D., E.S., C.G.H., J.C., and J.S.C. are employees of Mammoth Biosciences. C.Y.C.
536 is a member of the scientific advisory board for Mammoth Biosciences. The other
537 authors declare no competing interests.

538

539 **Data and Materials Availability**

540 All data needed to evaluate the conclusions in the paper are present in the paper and/or
541 the Supplementary Materials. The CasDx1 protein can be provided by Mammoth
542 Biosciences to the extent feasible, pending scientific review and a completed material

543 transfer agreement. Requests for the CasDx1 protein should be submitted to Janice

544 Chen at janice@mammothbiosci.com.

545

549 **Fig. S1. DETECTR[®] curves from gene fragments and heat-inactivated viral**
550 **cultures. (A)** Raw fluorescence curves from three Cas12 enzymes (CasDx1,
551 LbCas12a, AsCas12a) complexed with WT and MUT SNP gRNAs run on PCR-
552 amplified gene fragments representing WT and MUT SNP targets. **(B)** Raw
553 fluorescence curves from three Cas12 enzymes (CasDx1, LbCas12a, AsCas12a) on
554 eight heat-inactivated viral culture samples from various SARS-CoV-2 lineages, a no
555 target control (RT-LAMP) and CasDx1 detection controls (WT, MUT and NTC). CasDx1
556 replicates (n = 3), $\pm 1.0SD$


557

558

559

560

561




562

563

Fig. S2. Raw fluorescence RT-LAMP curves for each clinical sample. The raw

564 fluorescence RT-LAMP amplification curves for each of the clinical samples analyzed (n
565 = 3 replicates). Each line is representative of the median $\pm 1.0SD$ of the three RT-LAMP
566 replicates for each sample. RT-LAMP replicates that passed QC are represented in
567 navy blue and failed LAMP replicates are shown in orange. Only valid RT-LAMP
568 replicates were used in subsequent data analysis.



569
570 **Fig. S3. Raw fluorescence CasDx1 curves for each clinical sample amplified by**
571 **RT-LAMP.** Each clinical sample was amplified with RT-LAMP in triplicate, and the
572 resulting amplicons were detected by CasDx1 in triplicate. The raw fluorescence curves
573 show WT detection in blue and MUT detection in green. Each line is representative of
574 the median $\pm 1.0SD$ of the CasDx1 replicates (n = 3) for each WT and MUT guide for
575 each of the RT-LAMP replicates (n = 3), represented by different patterned lines.


576

577

578

579

580



581

582 **Fig. S4. Evaluation of the DETECTR® data analysis pipeline and making final calls.**

583 (A) Allele discrimination plot visualizing the scaled signals from the COVID Variant

584 DETECTR® assay on gene fragments. The allele discrimination plots represent scatter

585 plots of scaled WT and MUT fluorescence values plotted against each other. (B)

586 Contrast-Size plots of the COVID Variant DETECTR® assay data on gene fragments to

587 decrease ambiguity of the scaled signals, a ratio of the WT and MUT transformed

588 values are plotted against the average of the WT and MUT transformed values on the


589 MA plot. (C) Allele discrimination plot visualizing the scaled signals from the COVID

590 Variant DETECTR® assay on clinical sample. (D) MA plots of the COVID Variant

591 DETECTR® assay on the gene fragments (n = 30 WT; n = 30 MUT for each SNP) and

592 no template controls (n = 33 WT; n = 33 MUT for each SNP) used to test the data

593 analysis.



594

595 **Fig. S5. Highly specific detection by CasDx1 for each SNP on RT-LAMP replicates**

596 **from clinical samples. (A) The DETECTR[®] assay workflow from LAMP amplification to**

597 **SNP identification. (B) Schematic showing the relationship between clinical samples,**


598 LAMP replicates and CasDx1 replicates that culminate in a final SNP call. (C) Heat map
599 showing CasDx1 signal (n = 3) per every LAMP replicate (n = 3) for each SNP on every
600 clinical sample reflecting samples prior to discordance testing.

601

602

603

604



605

606 **Fig. S6. Determination of RT-LAMP threshold with a ROC curve.**

607 Thresholds for LAMP quality analysis were derived to determine which samples had
608 amplified sufficiently. The exact score value for this qualitative QC metric was
609 determined using a ROC analysis.

610

611

612

613



614

615 **Fig. S7. Visualization of SNP calls by the DETECTR[®] data analysis pipeline.** Box
616 plots of all the clinical samples illustrate the spread of the scaled signals for each of the
617 samples across the replicates in the experiment. SNP calls were made on each sample
618 agreement with the median values depicted on the box plot of the sample, which also
619 provided an analytical confirmation of the DETECTR[®] results.

620


621

622

623

624

625



626

627

628 **Fig. S8. Clinical evaluation results with clinical samples of uncertain integrity. (A)**

629 Raw fluorescence CasDx1 curves for the clinical samples with discordant DETECTR[®]

630 and WGS results. WT detection is represented by blue lines and MUT detection is

631 represented by green lines. Each line is representative of the median $\pm 1.0SD$ of the

632 CasDx1 replicates ($n = 3$) for each guide for each of the LAMP replicates ($n = 3$), and

633 each RT-LAMP replicate is represented by different patterned lines. (B) Visualization of

634 the COVID Variant DETECTR[®] and SARS-CoV-2 WGS assays showing the alignment

635 of final calls. Across all of the clinical samples in this cohort, 80 out of the 91 clinical

636 sample COVID Variant DETECTR[®] assay calls were consistent with the SARS-CoV-2

637 WGS calls. (C) Summary of re-testing of discordant samples from the original clinical

638 sample shows nearly all SNP discrepancies are resolved.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Patient sample	DETECTR (R)				Generic Lineage Classification	Whole Genome Sequencing					qPCR Ct
	SNP 452	SNP 484	SNP 501	SNP 452		SNP 484	SNP 501	Pango Lineage	Lineage/Variant Call		
COVID-01	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.1.519	N/A	16.2
COVID-02	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.1.222	N/A	17.2
* COVID-03	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.243	N/A	13.9
COVID-04	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.427	Epsilon	15.9
COVID-05	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.427	Epsilon	22.6
COVID-06	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.429	Epsilon	15.7
COVID-07	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.427	Epsilon	16.1
COVID-08	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.309	N/A	19.6
COVID-09	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.1.348	N/A	17.2
COVID-10	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.429	Epsilon	13.1
COVID-11	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	19.3
* COVID-12	WT	M	WT		Eta/Iota/Zeta	WT	M	WT	B.1.526	Iota	21.0
* COVID-13	M	WT	WT		Delta/Epsilon/Kappa	M	Q	WT	B.1.617.1	Kappa	17.3
COVID-14	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	14.9
COVID-15	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.575	N/A	18.4
COVID-16	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	21.6
COVID-17	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	13.2
COVID-18	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.280	N/A	13.9
COVID-19	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.9
* COVID-20	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	23.5
COVID-21	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	25.9
COVID-22	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	22.2
COVID-23	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.1
COVID-24	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	23.6
COVID-25	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	20.4
COVID-26	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	21.4
COVID-27	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	25.0
COVID-28	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	15.2
COVID-29	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	16.6
COVID-30	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.5
* COVID-31	WT	WT	M		Alpha	NoCall	WT	M	B.1.1.7	Alpha	23.6
COVID-32	WT	M	WT		Eta/Iota/Zeta	WT	M	WT	B.1.1.318	N/A	15.6
COVID-33	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	22.0
COVID-34	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.2
COVID-35	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	18.9
COVID-36	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	18.9
COVID-37	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	18.5
COVID-38	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	15.4
COVID-39	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	16.4
COVID-40	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	16.7
* COVID-41	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	24.2
COVID-42	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.7
COVID-43	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	15.3
COVID-44	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	17.9
COVID-45	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	16.6
COVID-46	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	23.2
COVID-47	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.526.1	N/A	16.6
COVID-48	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	13.7
COVID-49	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.9
COVID-50	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	15.8
COVID-51	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	15.8
COVID-52	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	18.1
COVID-53	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	22.9
COVID-54	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	22.0
COVID-55	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	19.4
* COVID-56	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.1
COVID-57	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.526.1	N/A	26.6
COVID-58	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.8
COVID-59	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	18.5
COVID-60	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	21.5
* COVID-61	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	16.9
COVID-62	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	14.1
* COVID-63	M	WT	WT		Delta/Epsilon/Kappa	M	Q	WT	B.1.617.2	Delta †	12.2
COVID-64	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	22.0
COVID-65	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.9
COVID-66	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	14.8
COVID-67	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.7
COVID-68	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	16.6
COVID-69	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	19.0
COVID-70	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.1
COVID-71	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	14.0
COVID-72	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	25.6
* COVID-73	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.7
COVID-74	WT	M	M		Beta/Gamma/Mu	WT	M	M	B.1.623	N/A	23.7
COVID-75	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.7
COVID-76	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	20.5
COVID-77	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	25.2
COVID-78	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.7
COVID-79	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	19.3
COVID-80	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.4
* COVID-81	WT	M	M		Beta/Gamma/Mu	WT	M	M	B.1.621	Mu	19.2
COVID-82	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	18.3
COVID-83	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	A.2.5	Delta	17.6
COVID-84	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	12.7
COVID-85	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.0
COVID-86	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	16.8
COVID-87	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.7
COVID-88	WT	M	WT		Eta/Iota/Zeta	WT	M	WT	B.1.526	Iota	14.8
COVID-89	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	20.5
COVID-90	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.6
COVID-91	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	A.2.5	Delta	15.6

640 **Table S1. Overall results summary of final SNP calls by the DETECTR[®] assay and**
641 **viral WGS.** A summary table of the final SNP calls from the DETECTR[®] assay and the
642 SARS-CoV-2 whole genome sequencing assay after discordant testing. The table
643 includes the lineage classification from DETECTR[®] calls as well as the PANGO lineage
644 and WHO labels assigned to the WGS calls. Ct values from running an FDA EUA
645 authorized SARS-CoV-2 RT-PCR assay, the Taqpath™ COVID-19 RT-PCR kit, are
646 shown. Discordant samples were reflexed back for reprocessing (*); COVID-63 was
647 classified as a Delta variant by WGS despite its Q484 SNP call. (†).
648

Type	Name	Sequence	Source
Guide RNA	Dx1_L452	UAAUUUCUACUAAGUGUAGAUuaaacaaucauacagguaa	Dharmacon or Synthego
	Dx1_R452	UAAUUUCUACUAAGUGUAGAUccGguauagauuguuagga	Dharmacon or Synthego
	Dx1_E484	UAAUUUCUACUAAGUGUAGAUaaaccuuaacaccuuaca	Dharmacon or Synthego
	Dx1_K484	UAAUUUCUACUAAGUGUAGAUaaaccuuUaacaccuuaca	Dharmacon or Synthego
	Dx1_N501	UAAUUUCUACUAAGUGUAGAUcaaccacuaaugguguugg	Dharmacon or Synthego
	Dx1_Y501	UAAUUUCUACUAAGUGUAGAUaaccUcuUaugguguuggu	Dharmacon or Synthego
	AsCas12a_L452	UAAUUUCUACUCUUGUAGAUuaaacaaucauacagguaa	Dharmacon or Synthego
	AsCas12a_R452	UAAUUUCUACUCUUGUAGAUccGguauagauuguuagga	Dharmacon or Synthego
	AsCas12a_E484	UAAUUUCUACUCUUGUAGAUaaaccuuaacaccuuaca	Dharmacon or Synthego
	AsCas12a_K484	UAAUUUCUACUCUUGUAGAUaaaccuuUaacaccuuaca	Dharmacon or Synthego
	AsCas12a_N501	UAAUUUCUACUCUUGUAGAUcaaccacuaaugguguugg	Dharmacon or Synthego
	AsCas12a_Y501	UAAUUUCUACUCUUGUAGAUaaccUcuUaugguguuggu	Dharmacon or Synthego
Reporter	ssDNA reporter	/5Alex594N/TTATTATT/3IAbrQSp/	IDT
Gene fragment	Mutant	tctgcttactaatgtctatgcagattcattgtaattagaggtgatgaagtcagacaaatcgctccag ggcaaaactggaaatattgctgattataataaaattaccagatgatttacaggctgcgttatagctt ggaattcaacaatcttgattctaaggttggtgtaattataattaccggtatagattgtaggaagctt aatcacaaccctttgagagagatatttcaactgaaatctatcaggccgtagcacaccttgaatg gtgtaaaggtttaattgtacttccittacaatcatatggtttccaaccactatggtggtggtacc aacatacacagtagtagtactttctttgaactctacatgca	Twist Biosciences
	Wild Type	tctgcttactaatgtctatgcagattcattgtaattagaggtgatgaagtcagacaaatcgctccag ggcaaaactggaaagattgctgattataataaaattaccagatgatttacaggctgcgttatagctt ggaattcaacaatcttgattctaaggttggtgtaattataattaccggtatagattgtaggaagctt aatcacaaccctttgagagagatatttcaactgaaatctatcaggccgtagcacaccttgaatg gtgtaaaggtttaattgtacttccittacaatcatatggtttccaaccactaattggtggtggtacc aacatacacagtagtagtactttctttgaactctacatgca	Twist Biosciences
LAMP Primer	set1-F3	CAAAGTGGAAAGATTGCTGA	Eurofins Genomics
	set1-B3	TACTACTACTCTGTATGGTTG	Eurofins Genomics
	set1-BIP	CCACCAACCTTAGAATCAAGATTGTTAAATTACCAGATGATTTACAGGC	Eurofins Genomics
	set1-FIP	TCAACTGAAATCTATCAGGCCGGGAAACCATATGATTGTTAAAGGAA	Eurofins Genomics
	set1-LF	TAGAATCCAAGCTATAACGCA	Eurofins Genomics
	set1-LB	TAGCACACCTTGAATGGTG	Eurofins Genomics
	set2-F3	TTCTAAGGTTGGTGGTAATTATAATTA	Eurofins Genomics
	set2-B3	CATTGAAGTTGAAATTGACACAT	Eurofins Genomics
	set2-BIP	TGGGTTGGAACCATATGATTGTTAAATCTATCAGGCCGGTAGC	Eurofins Genomics
	set2-FIP	TGTTGGTTACCAACCATACAGAGTAAGACTTTTTAGGTCCACAAACA	Eurofins Genomics
	set2-LF	GTAAGGAAAGTAACAATTAACCT	Eurofins Genomics
	set2-LB	AACTTCTACATGCACCAGCAA	Eurofins Genomics

649

650 **Table S2. Nucleic acid sequences used in this study.** A list of guide RNAs, reporter

651 molecules, LAMP primers and synthetic gene fragment targets with their respective

652 suppliers.

653

654 **REFERENCES**

655

- 656 1. S. P. Otto *et al.*, The origins and potential future of SARS-CoV-2 variants of
657 concern in the evolving COVID-19 pandemic. *Curr Biol* **31**, R918-R929 (2021).
- 658 2. R. P. Walensky, H. T. Walke, A. S. Fauci, SARS-CoV-2 Variants of Concern in
659 the United States-Challenges and Opportunities. *JAMA* **325**, 1037-1038 (2021).
- 660 3. X. Deng *et al.*, Genomic surveillance reveals multiple introductions of SARS-
661 CoV-2 into Northern California. *Science* **369**, 582-587 (2020).
- 662 4. S. Truelove *et al.*, Projected resurgence of COVID-19 in the United States in
663 July-December 2021 resulting from the increased transmissibility of the Delta
664 variant and faltering vaccination. *medRxiv*, (2021).
- 665 5. N. L. Washington *et al.*, Emergence and rapid transmission of SARS-CoV-2
666 B.1.1.7 in the United States. *Cell* **184**, 2587-2594 e2587 (2021).
- 667 6. M. Okereke, Spread of the delta coronavirus variant: Africa must be on watch.
668 *Public Health Pract (Oxf)* **2**, 100209 (2021).
- 669 7. E. C. Sabino *et al.*, Resurgence of COVID-19 in Manaus, Brazil, despite high
670 seroprevalence. *Lancet* **397**, 452-455 (2021).
- 671 8. V. Servellita *et al.*, Predominance of antibody-resistant SARS-CoV-2 variants in
672 vaccine breakthrough cases from the San Francisco Bay Area, California.
673 *medRxiv*, (2021).
- 674 9. T. Kustin *et al.*, Evidence for increased breakthrough rates of SARS-CoV-2
675 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nat Med*,
676 (2021).
- 677 10. J. Jung, H. Sung, S. H. Kim, Covid-19 Breakthrough Infections in Vaccinated
678 Health Care Workers. *N Engl J Med* **385**, 1629-1630 (2021).
- 679 11. C. M. Brown *et al.*, Outbreak of SARS-CoV-2 Infections, Including COVID-19
680 Vaccine Breakthrough Infections, Associated with Large Public Gatherings -
681 Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep*
682 **70**, 1059-1062 (2021).
- 683 12. F. Campbell *et al.*, Increased transmissibility and global spread of SARS-CoV-2
684 variants of concern as at June 2021. *Euro Surveill* **26**, (2021).
- 685 13. W. T. Harvey *et al.*, SARS-CoV-2 variants, spike mutations and immune escape.
686 *Nat Rev Microbiol* **19**, 409-424 (2021).
- 687 14. W. F. Garcia-Beltran *et al.*, Multiple SARS-CoV-2 variants escape neutralization
688 by vaccine-induced humoral immunity. *Cell* **184**, 2523 (2021).
- 689 15. D. Focosi, M. Tuccori, A. Baj, F. Maggi, SARS-CoV-2 Variants: A Synopsis of In
690 Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and
691 Monoclonal Antibodies. *Viruses* **13**, (2021).

- 692 16. B. B. Oude Munnink *et al.*, The next phase of SARS-CoV-2 surveillance: real-
693 time molecular epidemiology. *Nat Med* **27**, 1518-1524 (2021).
- 694 17. Rockefeller Foundation, "Implementation Framework: Toward a National Genomic
695 Surveillance Network," (Rockefeller Foundation, New York, 2021).
- 696 18. M. S. Verosloff *et al.*, CRISPR-Cas enzymes: The toolkit revolutionizing
697 diagnostics. *Biotechnol J*, e2100304 (2021).
- 698 19. J. P. Broughton *et al.*, CRISPR-Cas12-based detection of SARS-CoV-2. *Nat*
699 *Biotechnol* **38**, 870-874 (2020).
- 700 20. H. de Puig *et al.*, Minimally instrumented SHERLOCK (miSHERLOCK) for
701 CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants.
702 *Sci Adv* **7**, (2021).
- 703 21. M. Patchsung *et al.*, Clinical validation of a Cas13-based assay for the detection
704 of SARS-CoV-2 RNA. *Nat Biomed Eng* **4**, 1140-1149 (2020).
- 705 22. P. Fozouni *et al.*, Amplification-free detection of SARS-CoV-2 with CRISPR-
706 Cas13a and mobile phone microscopy. *Cell* **184**, 323-333 e329 (2021).
- 707 23. FDA. SARS-CoV-2 RNA DETECTR Assay, (2020),
708 <https://www.fda.gov/media/139937/download>, date accessed: November 14,
709 2021.
- 710 24. FDA. Sherlock™ CRISPR SARS-CoV-2 kit, (2020),
711 <https://www.fda.gov/media/137748/download>, date accessed: November 14,
712 2021.
- 713 25. J. S. Gootenberg *et al.*, Multiplexed and portable nucleic acid detection platform
714 with Cas13, Cas12a, and Csm6. *Science* **360**, 439-444 (2018).
- 715 26. C. Chiu, Cutting-Edge Infectious Disease Diagnostics with CRISPR. *Cell Host*
716 *Microbe* **23**, 702-704 (2018).
- 717 27. L. Zhang *et al.*, Ten emerging SARS-CoV-2 spike variants exhibit variable
718 infectivity, animal tropism, and antibody neutralization. *Commun Biol* **4**, 1196
719 (2021).
- 720 28. K. S. Corbett *et al.*, SARS-CoV-2 mRNA vaccine design enabled by prototype
721 pathogen preparedness. *Nature* **586**, 567-571 (2020).
- 722 29. F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19
723 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
- 724 30. R. Bos *et al.*, Ad26 vector-based COVID-19 vaccine encoding a prefusion-
725 stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular
726 immune responses. *NPJ Vaccines* **5**, 91 (2020).
- 727 31. F. Konings *et al.*, SARS-CoV-2 Variants of Interest and Concern naming scheme
728 conducive for global discourse. *Nat Microbiol* **6**, 821-823 (2021).
- 729 32. F. de Mello Malta *et al.*, Mass molecular testing for COVID19 using NGS-based
730 technology and a highly scalable workflow. *Sci Rep* **11**, 7122 (2021).

- 731 33. Z. Igloi *et al.*, Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for
732 SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. *Emerg*
733 *Infect Dis* **27**, 1323-1329 (2021).
- 734 34. C. Broccanello *et al.*, Comparison of three PCR-based assays for SNP
735 genotyping in plants. *Plant Methods* **14**, 28 (2018).
- 736 35. F. E. McGuigan, S. H. Ralston, Single nucleotide polymorphism detection: allelic
737 discrimination using TaqMan. *Psychiatr Genet* **12**, 133-136 (2002).
- 738 36. J. Singh, P. Pandit, A. G. McArthur, A. Banerjee, K. Mossman, Evolutionary
739 trajectory of SARS-CoV-2 and emerging variants. *Virology* **18**, 166 (2021).
- 740 37. J. Arizti-Sanz *et al.*, Equipment-free detection of SARS-CoV-2 and Variants of
741 Concern using Cas13. *medRxiv*, (2021).
- 742 38. W. A. Kibbe, OligoCalc: an online oligonucleotide properties calculator. *Nucleic*
743 *Acids Res* **35**, W43-46 (2007).
- 744 39. J. Quick *et al.*, Multiplex PCR method for MinION and Illumina sequencing of
745 Zika and other virus genomes directly from clinical samples. *Nat Protoc* **12**, 1261-
746 1276 (2017).
- 747 40. A. O'Toole *et al.*, Assignment of epidemiological lineages in an emerging
748 pandemic using the pangolin tool. *Virus Evol* **7**, veab064 (2021).
- 749 41. A. Rambaut *et al.*, A dynamic nomenclature proposal for SARS-CoV-2 lineages
750 to assist genomic epidemiology. *Nat Microbiol* **5**, 1403-1407 (2020).
- 751 42. R_Core_Team. R: A Language and Environmental for Statistical Computing,
752 (Vienna, Austria, 2018), <https://www.R-project.org>, date accessed: 11/26/21.
753